What are the recommended surgical approaches and pre‑operative assessment for invasive lobular carcinoma of the breast, including criteria for breast‑conserving surgery versus total mastectomy, sentinel lymph node biopsy, and the use of neoadjuvant endocrine or HER2‑targeted therapy?

Surgical Management of Invasive Lobular Carcinoma

For invasive lobular carcinoma (ILC), breast-conserving surgery with radiation is appropriate when negative margins can be achieved, but surgeons must anticipate higher re-excision rates and strongly consider oncoplastic techniques with routine shave margins to optimize outcomes. 1

Pre-operative Assessment

Essential Workup

• History and physical examination focusing on palpable masses (more common in ILC), family history for hereditary cancer risk, and bilateral breast assessment 2
• Bilateral diagnostic mammography with ultrasound as needed, recognizing that ILC poses diagnostic challenges due to its diffuse growth pattern 3, 4
• Core needle biopsy (not fine needle aspiration) for definitive pathologic diagnosis before any surgical procedure 2
• Pathologic assessment must include ER/PR status (mandatory), HER2 status, histologic grade, and tumor size 2

Role of MRI

Breast MRI should be strongly considered for ILC given the high rates of multifocal/multicentric disease (33%) and bilateral involvement (6%) 4. MRI improves tumor size staging accuracy and detects additional disease in 20% of patients, though it does not improve nodal staging accuracy 4. However, be aware that MRI has not been shown to decrease conversion to mastectomy or improve long-term outcomes 2.

Criteria for Breast-Conserving Surgery vs. Mastectomy

Contraindications to Breast Conservation

Absolute contraindications include 2:

• Multicentric tumors
• Large tumors (>3-4 cm) in small breasts when neoadjuvant therapy is not planned
• Inability to achieve negative margins after re-excision attempts
• Inflammatory breast cancer

Special Considerations for ILC

ILC presents unique surgical challenges due to its diffuse growth pattern 3, 1. The positive margin rate is significantly higher than ductal carcinoma, but this can be mitigated through:

• Oncoplastic surgical techniques (reduces positive margin odds by 60%, OR 0.4, p=0.008) 1
• Routine selective shave margins (reduces positive margin odds by 61%, OR 0.393, p=0.002) 1

With these techniques, breast conservation success rates of 75% are achievable in ILC 1. Re-excision should be performed to obtain negative margins (defined as no ink on tumor) in patients desiring breast conservation 2.

Axillary Staging

Sentinel Lymph Node Biopsy Indications

Sentinel lymph node biopsy (SLNB) is the preferred approach for clinically node-negative patients, even with multifocal or multicentric ILC 3. However, clinicians must be aware that ILC has a 24% rate of imaging-occult lymph node involvement 4.

When SLNB Should NOT Be Performed

SLNB is contraindicated in 2:

• Palpable axillary lymph nodes
• T3 or T4 tumors
• After neoadjuvant systemic treatment (outside clinical trials, though this is evolving)
• Prior axillary surgery or large biopsies
• During pregnancy or lactation

Omitting SLNB in Select Cases

SLNB may be omitted in highly selected postmenopausal patients ≥50 years with grade 1-2, ≤2 cm, HR-positive/HER2-negative tumors with negative pre-operative axillary ultrasound who undergo breast-conserving therapy 2.

Axillary Lymph Node Dissection

ALND should NOT be performed for patients without nodal metastases 2. For patients with 1-2 positive sentinel nodes undergoing breast-conserving surgery with whole-breast radiation, ALND may be omitted 2. For post-mastectomy patients with 1-2 positive sentinel nodes, post-mastectomy radiation with regional nodal irradiation may be offered instead of ALND 2.

Neoadjuvant Therapy Considerations

Neoadjuvant Endocrine Therapy

For postmenopausal women with ER-positive ILC, neoadjuvant endocrine therapy with an aromatase inhibitor is preferred over tamoxifen if preoperative systemic therapy is chosen 2. Aromatase inhibitors provide superior rates of breast-conserving surgery and objective response compared to tamoxifen 2.

Neoadjuvant Chemotherapy

Typical ILC (ER-positive/HER2-negative) shows poor response to neoadjuvant chemotherapy with 0% pathologic complete response rates 5. However, atypical ILC subtypes (ER-negative and/or HER2-positive) demonstrate significantly better response with 15% pathologic complete response rates (p=0.017) and lower mean residual cancer burden scores (2.46 vs 3.41, p=0.0365) 5.

Critical caveat: Even after neoadjuvant therapy, ILC has a 53.8% "underestimation" rate on imaging, with significantly higher additional mastectomy rates (p=0.025) compared to surgery-first approaches 6. This diagnostic challenge must be discussed with patients when considering neoadjuvant therapy.

HER2-Targeted Therapy

For HER2-positive ILC receiving neoadjuvant chemotherapy, trastuzumab must be incorporated for at least 9 weeks preoperatively, as this increases pathologic complete response rates from 26% to 65.2% (p=0.016) 2.

Surgical Technique Optimization

For ILC undergoing breast conservation, surgeons should routinely employ 1:

• Oncoplastic techniques to allow wider excisions while maintaining cosmesis
• Selective shave margins of the cavity
• Clip placement to mark tumor bed for radiation planning

These approaches achieve 75% breast conservation success rates with significantly lower positive margin rates 1.

Post-operative Management

Radiation therapy is strongly recommended after breast-conserving surgery (Level I, A evidence) 2. For mastectomy patients, post-mastectomy radiation is recommended for those with 4 or more positive nodes and suggested for T3 tumors regardless of nodal status 2.